Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34⁺ cells
J. Clin. Invest. Laure A. Moutouh-de Parseval, et al. 118:248 doi:10.1172/JCI32322 [Go to this article.]

Figure 7
Effect of pomalidomide, lenalidomide, and other HbF inducers on HbF expression during erythroid differentiation of CD34⁺ cells from SCD patients. CD34⁺ cells were isolated from the PBMCs of SCD patients, expanded for 6 days, and differentiated to the erythroid lineage. (A) Expression of HbF was monitored by flow cytometry after 6 days of erythroid differentiation in the presence of increasing concentrations of pomalidomide, lenalidomide, HU, butyrate, and 5-azacytidine (SCD patient no. 5 is represented). Values represent mean ± SEM (n = 3). (B) Histograms of the percentage of cells expressing HbF in response to single or combination treatment with HU and pomalidomide from SCD patient no. 2 are represented. The experiments were repeated on samples from at least 2 different donors with similar results.